All In Biotech

Drug Trial Radar · NCT01508026

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension

Last checked: Nov 20, 2026Latest source record: Apr 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,161

Actual

Start

Jan 2012

Primary completion

Mar 2013

Study completion May 2013

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.

Conditions

  • Stage 1 Hypertension
  • Stage 2 Hypertension

Interventions

  • Nebivolol and Valsartan 1Drug

    Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration

  • Nebivolol and Valsartan 2Drug

    Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration

  • Nebivolol and Valsartan 3Drug

    Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration

  • Nebivolol 1Drug

    Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration

  • Nebivolol 2Drug

    Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration

  • Valsartan 1Drug

    Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration

  • Valsartan 2Drug

    Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration

  • PlaceboDrug

    Dose matched placebo, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Sitting Diastolic Blood Pressure (DBP)Time frame: from basline to Week 8

Locations

413 sites in 1 country. Site status is shown where the registry gives one.

  • Forest Investigative Site 1750

    Birmingham, Alabama

  • Forest Investigative Site 1038

    Birmingham, Alabama

  • Forest Investigative Site 1308

    Birmingham, Alabama

  • Forest Investigative Site 1192

    Birmingham, Alabama

  • Forest Investigative Site 1005

    Birmingham, Alabama

  • Forest Investigative Site 1047

    Foley, Alabama

  • Forest Investigative Site 1717

    Gulf Shores, Alabama

  • Forest Investigative Site 1056

    Mobile, Alabama

  • Forest Investigative Site 1719

    Muscle Shoals, Alabama

  • Forest Investigative Site 1145

    Glendale, Arizona

  • Forest Investigative Site 1703

    Goodyear, Arizona

  • Forest Investigative Site 1757

    Mesa, Arizona

  • Forest Investigative Site 1170

    Phoenix, Arizona

  • Forest Investigative Site 1238

    Phoenix, Arizona

  • Forest Investigative Site 1204

    Phoenix, Arizona

  • Forest Investigative Site 1755

    Phoenix, Arizona

  • Forest Investigative Site 1259

    Phoenix, Arizona

  • Forest Investigative Site 1001

    Phoenix, Arizona

  • Forest Investigative Site 1078

    Scottsdale, Arizona

  • Forest Investigative Site 1225

    Tempe, Arizona

  • Forest Investigative Site 1712

    Tempe, Arizona

  • Forest Investigative Site 1089

    Tempe, Arizona

  • Forest Investigative Site 1065

    Tucson, Arizona

  • Forest Investigative Site 1340

    Tucson, Arizona

  • Forest Investigative Site 1331

    Tucson, Arizona

  • Forest Investigative Site 1290

    Little Rock, Arkansas

  • Forest Investigative Site 1138

    Little Rock, Arkansas

  • Forest Investigative Site 1371

    Pine Bluff, Arkansas

  • Forest Investigative Site 1220

    Searcy, Arkansas

  • Forest Investigative Site 1063

    Buena Park, California

  • Forest Investigative Site 1743

    Burbank, California

  • Forest Investigative Site 1006

    Carmichael, California

  • Forest Investigative Site 1384

    Chino, California

  • Forest Investigative Site 1190

    Chula Vista, California

  • Forest Investigative Site 1178

    Costa Mesa, California

  • Forest Investigative Site 1043

    Diamond Bar, California

  • Forest Investigative Site 1362

    Encinitas, California

  • Forest Investigative Site 1144

    Fresno, California

  • Forest Investigative Site 1095

    Fresno, California

  • Forest Investigative Site 1710

    Garden Grove, California

Showing 40 of 413 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.